Immune checkpoint inhibitors are a type of cancer treatment that help the immune system recognize and attack cancer cells. They work by blocking proteins that normally keep immune responses in check, allowing T-cells to become more active against tumors. This approach can enhance the body’s natural ability to fight cancer. These therapies have shown promise in treating various cancers, including melanoma, lung cancer, and bladder cancer. By targeting specific checkpoints, such as PD-1 or CTLA-4, these drugs can improve patient outcomes and have become an important part of modern oncology.